Article
Tumor Mutational Burden Predicts Survival In Patients With Low Grade Gliomas Expressing Mutated IDH1
2020-01-23
Abstract excerpt
<h4>ABSTRACT</h4> Gliomas are the most common primary brain tumors. High Grade Gliomas have a median survival of 18 months, while Low Grade Gliomas (LGG) have a median survival of ∼7.3 years. Seventy-six percent of patients with LGG express mutated isocitrate dehydrogenase (mIDH1) enzyme (IDH1 R132H ). Survival of these patients ranges from 1-15 years, and tumor mutational burden ranges from 8 to 447 total somatic...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 9684d2a8-6d32-55fd-9b77-9026ee532044
- DOI
- 10.1101/2020.01.20.20016766
